Table 1.
Baseline characteristics and final visual outcome
| Group A. In-house (n = 50) | Group B. Referred (n = 50) | P value | |
|---|---|---|---|
| Mean age (years) ± SD | 58.13 ± 12.81 | 58.74 ± 13.29 | 0.41 |
| Mean baseline BCVA logMAR (ETDRS equivalent) ± SD | 1.99 (20/1954) ± 0.61 | 1.96 (20/1824) ± 0.45 | 0.48 |
| Male: Female | 29: 21 | 26: 24 | 0.55 |
| Mean event to report time days (± SD, 95% CI) | 6.83 (±7.61; 95% CI, 4.57 – 9.09) | 13.63 (±11.67; 95% CI, 9.95 – 17.31) | 0.002* |
| Number of diabetics | 6 | 2 | 0.14 |
| Inflammatory score (Mean ± SD) | 17.85 ± 5.83 | 18.18 ± 7.35 | 0. 24 |
| Final best corrected visual acuity | |||
| ≥ 20/200 | 29 of 48 (60.42%; 95% CI, 45.30-73.89) | 22 of 50 (44%; 95% CI, 30.27-58.65) | 0.11 |
| ≤ 20/400 | 18 of 48 (37.5%; 95% CI, 24.32-54.67) | 26 of 50 (52%; 95% CI, 37.58-66.12) | 0.62 |
*Statistically significant